Rofecoxib

Bibliography

• LAWRENCE RC, HELMICK CG, ARNETT FC et al.: Estimates of the prevalence of arthritis and selected musculo-skeletal disorders in the United States. Arthritis Rheum. (1998) 41:778-799. Exp. Opin. Pharmacother. (2000) 1(5)
   Google Scholar
• SIMON LS: Toxicities of the non-steroidalanti-inflammatory drugs. Curr. Opin. Rhematol. (1992) 4:301–308.
   PubMedGoogle Scholar
• MCCARTHY D: Non-steroidal anti-inflammatorydrug-related gastrointestinal toxicity: definitions and epidemiology. Am. J. Med. (1998) 105(Suppl. 3A):35–95.
   Google Scholar
• FOSSLIEN E: Adverse effects of non-steroidal anti-inflammatory drugs on the gastrointestinal system. Ann. Clin. Lab. Sci. (1998) 28:67-81. Excellent review of mechanisms and prevalence of NSAID GI toxicity.
   Google Scholar
• LAINE L: non-steroidal anti-inflammatory drug gastro-pathy. Gastrointest. Endosc. Clin. N. Am. (1996) 6:489–504.
   PubMedGoogle Scholar
• FRIES JF, WILLIAMS DA, BLOCH DA et al.: NSA1D associ-ated gastropathy: incidence and risk factor models. Am. J. Med. (1991) 91:213–221.
   PubMed Web of Science ®Google Scholar
• FRIES JF: NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal./ Rheumatol. (1991) 18\(Suppl. 28):6–10
   Google Scholar
• •Best estimate of NSAID risks based on large data-base.
   Google Scholar
• GABRIEL SE, JAAKKIMAINEN L, BOMBARDIER C: Risks for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann. Intern. Med. (1991) 115:787–796.
   PubMed Web of Science ®Google Scholar
• HAWKEY CJ: Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scan.J.Gastroenteol. (1996) 220:124–127.
   Google Scholar
• BLOWER AL, BROOKS A, FENN GC et al.: Emergencyadmissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther. (1997) 11:283–291.
   PubMed Web of Science ®Google Scholar
• LANZA FL AND THE MEMBERS OF THE AD HOC COMMITTEE ON PRACTICE PARAMETERS OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY: A guideline for the treatment and prevention of NSAID-induced ulcers. Am. J. Gastroenterology (1998) 93:2037–2046.
   PubMedGoogle Scholar
• ••Overview of risks and risk-management for NSAID GItoxicity.
   Google Scholar
• SINGH G, RAMEY DR, MORFELD D eta/.: Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch. Intern. Med. (1996) 156:1530–1536.
   Google Scholar
• SILVERSTEIN FE, GRAHAM DY, SENIOR JR et al.:Misoprostyl reduces serious gastrointestinal compli-cations in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. A random-ized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1995) 123:241–249.
   PubMed Web of Science ®Google Scholar
• JOHNSON RE, HORBROOK MC, HOOKER RS, WOODSONGT, SCHNEIDMAN R: Analysis of the costs of NSAID-associated gastropathy. Pharmacoeconomics (1997) 12:76–88.
   PubMed Web of Science ®Google Scholar
• HENRY D, LIM LL-Y, RODRIGUEZ LAG et al Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br. Med. J. (1996) 313:1563–1566.
   Google Scholar
• ALLISON MC, HOWATSON AS, TORRANCE CJ et al.: Gastrointestinal damage associated with the use of NSAID. N. Engl. J Med. (1992) 327:749–754.
   PubMed Web of Science ®Google Scholar
• VANE JR, BOTTING RM: Biological properties of cyclooxygenase products. In: Lipid Mediators. Cunningham FM (Ed.), Academic Press, San Diego, CA, USA (1994):61–97.
   Google Scholar
• •Overview of the roles of prostanoids in basal and regulated processes.
   Google Scholar
• SEMBLE EL, WU WC: Prostaglandins in the gut and their relationship to non-steroidal anti-inflammatory drugs. Bailliere's Clin. Rhematol. (1989) 3:247–69.
   PubMedGoogle Scholar
• GARELL S, MATARESE RA: Renal effects of prosta-glandins and clinical adverse effects of non-steroidal anti-inflammatory agents. Medicine (1984) 63:165–181.
   PubMedGoogle Scholar
• PORTONOVA JY, ZHANG GD, ANDERSON S et al.: Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia and IL-6 production in vivo. J Exp. Med. (1996) 184:883–891.
   PubMedGoogle Scholar
• NEEDLEMAN P, ISAKSON PC: The discovery and function of COX-2. J. Rheum. (1997) 24:6–8.
   PubMedGoogle Scholar
• •Review of the discovery of COX-2, its expression and function.
   Google Scholar
• CROFFORD LJ: COX-1 and COX-2 tissue expression: implications and predictions./ Rheum. (1997) 24:15–19.
   Web of Science ®Google Scholar
• ••Excellent review of COX-1 and COX-2 expression, whichpermits prediction of drug effects.
   Google Scholar
• SMITH G, ROBERTS R, HALL C eta/.: Reversible ovulatory failure associated with the development of lutenized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. B. J. Rheumatol. (1996) 35:458–462.
   Google Scholar
• SCHMASSMANN A: Mechanisms of ulcer healing and effects of non-steroidal anti-inflammatory drugs. Am. J. Med. (1998) 104:43S–51S.
   Google Scholar
• SAIRANEN T, RISTIMAKI A, KARJALAINEN-LINDSBERG ML et al.: Cyclooxygenase is induced globally in infarcted human brain. Ann. Neurol. (1998) 43:783–747.
   Google Scholar
• WU KK: Biochem Pharmacol of non-steroidal anti-inflammatory drugs. Biochem. Pharmacol. (1998) 55:543–547
   PubMedGoogle Scholar
• CHAN CC, BOYCE S, CHARLESON S et al.: Rofecoxib: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. (1999) 290:551–560.
   PubMed Web of Science ®Google Scholar
• •Pharmacology of rofecoxib.
   Google Scholar
• WARNER TD, GIULIANO F, VOJNOVIC I et al.: Non-steroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal activity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA (1999) 96:7563–7568.
   PubMed Web of Science ®Google Scholar
• ••The most complete analysis of relative inhibition of COX-1and COX-2 by NSAIDs.
   Google Scholar
• EHRICH EW, DALLOB A, DE LEPELEIRE I et al Characteri- zation of rofecoxib as a cyclooxygenase to isoform Exp. Opin. Pharmacother. (2000) 1(5) C Ashley Publications Ltd. All rights reserved. inhibitor and demonstration of analgesia in the dental pain model. Clin. Pharmacol. Ther. (1999) 65:336–347.
   Google Scholar
• ••Efficacy data.
   Google Scholar
• CRYER B, GOTTESDIENER K, GERTZ B et al.: Effects of a novel cyclooxygenase-2 inhibitor on gastric mucosal prostaglandin synthesis in healthy humans. Am. J. Gastroenterol. (1996) 91:1907 #104.
   Google Scholar
• SCHWARTZ JI, VAN HECKEN A, DE LEPELEIRE I et al.:Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on cox-2 vs. cox-1 in healthy female volunteers. XIV European League Against Rheumatism Congress (1999). Abstract 857.
   Google Scholar
• MERCK AND COMPANY, INC. Vioxx prescribing informa-tion. New Jersey, USA (1999).
   Google Scholar
• HUNT R, BOWEN B, JAMES C eta: COX-2 specific inhibi-tion with MK-0966 25mg or 50mg qd over 4 weeks does not increase faecal blood loss. Am. J. Gastroenterology (1998) 93:1671. Abstract 247.
   Google Scholar
• •Safety data.
   Google Scholar
• BJARNSON I, SIGTHORSSON G, CRANE R et al.: COX-2 Specific inhibition with MK-0966 25 or 50 mg qd does not increase intestinal permeability: A controlled study with placebo (PBO) and indomethacin 50 mg t.i.d (INDO). Am. J. Gastroenterol. (1998) 93:1670. Abstract 246.
   Google Scholar
• NASIR K, KHAN M, VENTURINI CM et al.: Interspecies differences in renal localization of cyclooxygenase isoforms; implications in NSAIDs-related nephrotox-icity. Toxic Pathology (1998) 26(5):612–620.
   PubMedGoogle Scholar
• SWAN SK, LASSETER KC, RYAN CF et al.: Renal effects of multiple-dose rofecoxib, a COX-2 inhibitor in elderly patients. J. Am. Soc. Nephrol. (1999) 10\(Suppl. 696):641.
   Google Scholar
• MURPHY MG, KIVITZ AJ & THE ROFECOXIB BONE STUDY GROUP: The effects of rofecoxib, a cyclooxyge-nase specific inhibitor versus ibuprofen on biochemical indices of bone turnover in patients with osteoarthritis. J. Bone Miner. Res. (1999) 14(Suppl.):5A134. Abstract.
   Google Scholar
• SCHWARTZ JL, WALDMAN S, SLAUGHTER D et al.: Influence of the selective cyclooxygenase-2 inhibitor, MK-0966 on cytochrome P450 (CYP) activity. Arch. Pharmacol. (1998) 358\(Suppl. 2):R 509. Abstract.
   Google Scholar
• SCOTT LJ, LAMB HM: Rofecoxib. Drugs (1999) 58(3):499–505.
   PubMedGoogle Scholar
• FRICKE J, MORRISON BW, FITE S et al.: MK-966 versus naproxen sodium 550 mg in post-surgical dental pain. Am. Soc. Clin. Pharmacol. Therapeut. (1999) 65:119. Abstract PI–7.
   Google Scholar
• MORRISON BW, CHRISTENSEN S, YUAN W et al.: Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental pain: a randomized, controlled trial. Clin. Therapeut. (1999) 21:943–953.
   PubMed Web of Science ®Google Scholar
• •Efficacy data.
   Google Scholar
• MALSTROM K, DANIELS S, KOTEY P et al.: Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibi-tors, in postoperative dental pain: a randomized, placebo- and active-comparator- controlled clinical trial. Clin. Therapeut. (1999) 21:1653–1663.
   PubMedGoogle Scholar
• •Efficacy data.
   Google Scholar
• REICIN AS, BROWN J, JOVE M et al.: The cox-2 specific inhibitor, rofecoxib, was effective in the treatment of postorthopedic surgical pain. Arthritis Rheum. (1999) 42:S268. Abstract 1186.
   Google Scholar
• SCHWARTZ JI, CHAN CC, MUKHOPADHYAY S et al.: Cycooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin. Pharm. Ther. (1999) 65:653–660.
   PubMedGoogle Scholar
• •Efficacy data.
   Google Scholar
• MORRISON BW, DANIELS SE, KOTEY P et al.: Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet. Gynecol. (1999) 94:504–508.
   PubMed Web of Science ®Google Scholar
• •Efficacy data.
   Google Scholar
• SCHNITZER TJ, TRUITT K, FLEISCHMANN R et al.: The safety profile, tolerability and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin. Therapeut. (1999) 21:1688–1702.
   PubMed Web of Science ®Google Scholar
• •Efficacy data.
   Google Scholar
• MERCK AND CO., INC. (Mark J Greco, MD, Senior Director, Medical Services. Letter. March 27, 2000.
   Google Scholar
• EHRICH EW, SCHNITZER TJ, MCILWAN H et al.: Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo-controlled pilot study of rofecoxib. J. Rheum. (1999) 26:2438–2447.
   PubMed Web of Science ®Google Scholar
• •Efficacy data.
   Google Scholar
• EHRICH EW, SCHNITZER T, KIVITZ A et al.: MK-966, a highly selective cox-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a six-week placebo-controlled study. Arthritis Rheum. (1997) 40:585. Abstract 330.
   Google Scholar
• SAAG K, FISHER C, MCKAY J et al.: MK-966, a specificcox-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoar-thritis in a 6-week controlled clinical trial. Arthritis Rheum. (1998) 41:S196. Abstract 984.
   Google Scholar
• GEBA GP, POLIS AB, DIXON ME et al.: Rofecoxib resultsin superior clinical response to nabumetone in the treatment of osteoarthritis. Arthritis Rheum. (1999) 42:S144. Abstract 440.
   Google Scholar
• CANNON G, CALDWELL J, HOLT et al.: MK-0966, aspecific cox-2 inhibitor, has clinical efficay comparable to diclofenac in the treatment of knee and hip OA in a 26-week controlled clinical trial. Arthritis Rheum. (1998) 41:S196. Abstract 983.
   Google Scholar
• ACEVIDO E, ROMANOWICZ A, VAN DER HEIJDE D et al.: Rofecoxib, a cox-2 specific inhibitor, had clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in a one-year controlled clinical trial. XIV European League Against Rheumatism Congress, 2000. Abstract 858.
   Google Scholar
• DANIELS B, KRUPA D, EHRICH E et al.: Clinical response of OA patients who use acetaminophen when random-ized to rofecoxib or ibuprofen. Arthritis Rheum. 42:S143. Abstract 436. C Ashley Publications Ltd. All rights reserved.
   Google Scholar
• HUNT R, BOWEN B, JAMES RN et al.: Cox-2 specific inhibition with MK-0966 25 or 50 mg over 4 weeks does not increase fecal blood loss: a controlled study with placebo and ibuprofen 800 mg t.i.d. Am. J. Gastroent. (1998) 93:1671 Abstract 247.
   Google Scholar
• LANZA FL, RACK MF, SIMON TJ et al.: Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastrointestinal damage than either aspirin or ibuprofen. Aliment. Pharmacol. Ther. (1999) 13:761–767.
   PubMed Web of Science ®Google Scholar
• •Safety data.
   Google Scholar
• LAINE L, HARPER S, SIMON T et al.: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoar-thritis. Gastroenterology (1999) 117:776–783.
   PubMed Web of Science ®Google Scholar
• •Safety data.
   Google Scholar
• LANGMAN, MICHAEL J, DM JENSEN ET AL.: Adverse Upper Gastrointestinal effects of rofecoxib compared with NSAIDs. JANIA 282:1929–1933.
   Google Scholar
• •Overview of safety data from all studies.
   Google Scholar
• FURST DE, HILLSON JL: What is the role of selective cox-2 inhibitors in the spectrum of NSAID therapy. Rheumatology Grand Rounds (1999) 1:1–10.
   Google Scholar
• GUPTA S, MCCUNE WJ, KAPLAN MJ et al.: Thrombosis and ischemia in patients with systemic lupus erythe-matosis treated with celecoxib: a series of two cases. Arthritis Rheum. (1999) 42:S149 (abstract 473).
   Google Scholar
• DE POUVOURVILLE G, TASCH RF: The economic consequences of NSAID-induced gastrointestinal damage. Eur. J. Rheumatol. Inflamm. (1993) 13:33–40
   PubMedGoogle Scholar
• KNILL-JONES RP: The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G de Pourvourville. Scand. J. Rheumatol. (1992) 21596:59–62.
   Google Scholar
• KOLODNY AL, KLIPPER A: Final report on the cost of treating arthritic disease: comparison between saucy-dates and non-salycilate non-steroidal anti-inflammatory drugs. Semin. Arthritis Rheum. (1985) 14S1:20–24.
   Google Scholar